| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ISG15 |
| Uniprot No | P05161 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-157aa |
| 氨基酸序列 | GWDLTVKMLAGNEFQVSLSSSMSVSELKAQITQKIGVHAFQQRLAVHPSG VALQDRVPLASQGLGPGSTVLLVVDKCDEPLSILVRNNKGRSSTYEVRLT QTVAHLKQQVSGLEGVQDDLFWLTFEGKPLEDQLPLGEYGLKPLSTVFMN LRLRGG |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ISG15重组蛋白的3篇代表性文献及其摘要概括：
1. **"ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response"**
- **作者**: Zhang D, et al. (2008)
- **摘要**: 该研究通过重组ISG15蛋白，揭示了其在抗病毒天然免疫中的作用机制，证明ISG15通过抑制E3泛素连接酶Nedd4的活性，促进干扰素信号通路，从而抑制病毒复制。
2. **"Mechanism of ISG15 activation by the interferon-inducible ubiquitin-like modifier activating enzyme UbE1L"**
- **作者**: Ritchie KJ, et al. (2014)
- **摘要**: 文章利用重组ISG15蛋白及其活化酶UbE1L，系统解析了ISG15的酶促活化过程，发现UbE1L通过ATP依赖的硫酯键形成激活ISG15.为研究ISG15的翻译后修饰功能提供理论基础。
3. **"Type I interferon induces a ISG15 conjugation complex distinct from the E1-E2-E3 enzyme cascade"**
- **作者**: Sanyal S, et al. (2016)
- **摘要**: 该研究通过体外重组实验发现，ISG15的结合过程可能不依赖传统泛素化酶级联反应，而是通过新型复合体完成，为ISG15的独特生物学功能提供了新视角。
*注：以上文献信息为示例性内容，实际引用需核对具体论文数据库(如PubMed)以确保准确性。如需更近期文献，可补充2020年后关于ISG15重组蛋白结构解析或COVID-19相关抗病毒机制的研究。*
ISG15 (Interferon-Stimulated Gene 15) recombinant protein is a key molecule in understanding innate immune responses, particularly those triggered by viral infections and cellular stress. Discovered in the 1980s as one of the earliest interferon (IFN)-induced genes, ISG15 encodes a 15-kDa protein structurally resembling ubiquitin, with two tandem ubiquitin-like domains. Unlike ubiquitin, which primarily tags proteins for degradation, ISG15 functions as a ubiquitin-like modifier (UBL) through a process called ISGylation. This involves conjugating ISG15 to target proteins via a cascade involving E1 (UBE1L), E2 (UBCH8), and E3 ligases, modulating their stability, localization, or activity. Notably, ISG15 also exists in a free, unconjugated form, acting as a cytokine to stimulate immune cells like natural killer (NK) cells and T-cells.
Recombinant ISG15 protein is typically produced in *E. coli* or mammalian expression systems, enabling studies of its dual roles. Its antiviral properties are well-documented: ISG15-deficient mice show heightened susceptibility to influenza, HIV, and SARS-CoV-2. underscoring its role in restricting viral replication. In cancer, ISG15’s expression correlates with tumor progression or suppression depending on context, making it a potential therapeutic target. Recombinant ISG15 facilitates mechanistic studies, such as identifying ISGylation substrates or exploring cross-talk with other post-translational modifiers like ubiquitin and SUMO.
Recent research highlights its extracellular signaling function, where recombinant ISG15 binds to LFA-1 integrin on immune cells, enhancing IFN-γ production. This duality—intracellular modification and extracellular signaling—positions ISG15 as a versatile immune regulator. Clinically, recombinant ISG15 aids in developing diagnostics or therapies, including combinational approaches with immune checkpoint inhibitors. Despite progress, challenges remain in mapping its context-specific roles and therapeutic applications, driving ongoing interest in this multifunctional protein.
×
